Improved clinical outcomes with abciximab therapy in acute myocardial infarction: A systematic overview of randomized clinical trials AMERICAN HEART JOURNAL Kandzari, D. E., Hasselblad, V., Tcheng, J. E., Stone, G. W., Califf, R. M., Kastrati, A., Neumann, F. J., Brener, S. J., Montalescot, G., Kong, D. F., Harrington, R. A. 2004; 147 (3): 457-462


Investigations of glycoprotein (GP) IIb/IIIa inhibition in primary percutaneous coronary intervention (PCI) have suggested the efficacy of abciximab in improving clinical and angiographic outcomes, but sample-size limitations and variability in trial design preclude the ability to generalize these results to a broader patient population.Meta-analytic techniques were used to evaluate clinical outcomes from randomized trials comparing GP IIb/IIIa inhibition with placebo or control therapy in primary PCI for acute myocardial infarction (MI).In 3266 patients, treatment with abciximab significantly reduced the 30-day composite end point of death, reinfarction, or ischemic or urgent target-vessel revascularization (TVR; odds ratio [OR], 0.54; 95% CI, 0.40-0.72), with trends toward reduced 30-day death and death or reinfarction. Abciximab resulted in an increased likelihood of major bleeding (OR, 1.74; 95% CI, 1.11-2.72). By 6 months, abciximab significantly reduced the occurrence of death, reinfarction, or any TVR (OR, 0.80; 95% CI, 0.67-0.97), and there were positive trends favoring a decrease in mortality alone and the composite of death or reinfarction.Treatment with abciximab significantly reduces early adverse ischemic events, a clinical benefit that is maintained at 6-month follow-up. These findings support the use of adjunctive GP IIb/IIIa inhibition in primary PCI.

View details for DOI 10.1016/j.ahj.2003.08.011

View details for Web of Science ID 000220539400017

View details for PubMedID 14999194